Covid 19 Research using Clinical Trials (Home Page)
ChloroquineWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (23)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug889 | Nitazoxanide Wiki | 0.53 |
| drug715 | Ivermectin Wiki | 0.50 |
| drug618 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.50 |
| drug619 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.50 |
| drug1611 | non interventional Wiki | 0.35 |
| drug283 | Canakinumab Injection 300mg Wiki | 0.35 |
| drug514 | Fibrin generation markers assays Wiki | 0.35 |
| drug284 | Canakinumab Injection 600mg Wiki | 0.35 |
| drug1393 | Thrombin Generation Assay (TGA) Wiki | 0.35 |
| drug1395 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.35 |
| drug694 | Intermediate dose thromboprophylaxis Wiki | 0.35 |
| drug953 | Other drugs Wiki | 0.35 |
| drug1284 | Standard of Care thromboprophylaxis Wiki | 0.35 |
| drug1394 | Thrombin generation test assay Wiki | 0.35 |
| drug1565 | hospitalized children with Covid19 Wiki | 0.35 |
| drug1687 | ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. Wiki | 0.35 |
| drug884 | Niclosamide Wiki | 0.25 |
| drug442 | Doxycycline Wiki | 0.20 |
| drug505 | Favipiravir Wiki | 0.11 |
| drug1042 | Placebos Wiki | 0.09 |
| drug1035 | Placebo oral tablet Wiki | 0.07 |
| drug129 | Azithromycin Wiki | 0.07 |
| drug1016 | Placebo Wiki | 0.05 |
Correlated MeSH Terms (16)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020141 | Hemostatic Disorders NIH | 0.43 |
| D001778 | Blood Coagulation Disorders NIH | 0.43 |
| D004211 | Disseminated Intravascular Coagulation NIH | 0.41 |
| D001416 | Back Pain NIH | 0.35 |
| D056660 | Hereditary Autoinflammatory Diseases NIH | 0.35 |
| D001528 | Behcet Syndrome NIH | 0.35 |
| D010505 | Familial Mediterranean Fever NIH | 0.35 |
| D017116 | Low Back Pain NIH | 0.35 |
| D002006 | Brucellosis NIH | 0.35 |
| D010146 | Pain NIH | 0.35 |
| D058070 | Asymptomatic Diseases NIH | 0.25 |
| D016638 | Critical Illness NIH | 0.07 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D014777 | Virus Diseases NIH | 0.05 |
| D007239 | Infection NIH | 0.02 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001928 | Abnormality of coagulation HPO | 0.53 |
| HP:0005521 | Disseminated intravascular coagulation HPO | 0.41 |
There are 8 clinical trials
Clinical Trials
1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19
COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs
Primary Outcomes
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 months2 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
NCT04346667 SARS-CoV-2 Coronavirus Infection Asymptomatic Condition COVID-19 Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Asymptomatic Diseases
Primary Outcomes
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysSecondary Outcomes
Description: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 days3 Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.
NCT04349371 COVID Drug: Chloroquine Drug: Placebo oral tablet
Primary Outcomes
Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.
Measure: Number of symptomatic illness in at risk healthcare workers Time: Up to 3 monthsDescription: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.
Measure: Number of healthcare workers with symptomatic COVID infections Time: Up to 3 monthsDescription: Severe illness includes worsening of symptoms.
Measure: Number of severe illness in at risk healthcare workers Time: Up to 3 monthsSecondary Outcomes
Description: Confirmation with polymerase chain reaction (PCR) when available.
Measure: Number of sero-conversions in at risk healthcare workers Time: Up to 3 monthsDescription: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.
Measure: Percentage of patients with adverse events Grade 3 or higher Time: Up to 3 monthsDescription: GI intolerance to chloroquine will be documented and recorded.
Measure: Percentage of patients with GI intolerance Time: Up to 3 months4 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
NCT04351191 Sars-CoV2 Symptomatic Condition Covid-19 Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo
Primary Outcomes
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR result Time: 6th and 7th daySecondary Outcomes
Description: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Death
Measure: Mortality Time: 30 days5 Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment
Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment
NCT04351347 COVID Drug: Chloroquine Drug: Nitazoxanide Drug: Ivermectin
Primary Outcomes
Description: Number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 months6 Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 Treatment
Chloroquine in COVID-19 treatment
NCT04353336 COVID-19 Coronavirus Infection Drug: Chloroquine MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome
Primary Outcomes
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 months7 Novel Treatment Regimens in Treatment of COVID-19
Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome
Primary Outcomes
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 months8 The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment
Efficacy of Ivermectin and Doxycycline in COVID-19 treatment
NCT04403555 COVID Drug: Ivermectin Drug: Doxycycline Drug: Chloroquine
Primary Outcomes
Description: The number of patients with negative pcr
Measure: The number of patients with resolved viral infection Time: 6 months